Last reviewed · How we verify

Ethyl Chloride Topical Aerosol Anesthetic

Brooke Army Medical Center · Phase 1 active Small molecule

Ethyl Chloride Topical Aerosol Anesthetic is a Small molecule drug developed by Brooke Army Medical Center. It is currently in Phase 1 development. Also known as: Study Device or Product B.

At a glance

Generic nameEthyl Chloride Topical Aerosol Anesthetic
Also known asStudy Device or Product B
SponsorBrooke Army Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ethyl Chloride Topical Aerosol Anesthetic

What is Ethyl Chloride Topical Aerosol Anesthetic?

Ethyl Chloride Topical Aerosol Anesthetic is a Small molecule drug developed by Brooke Army Medical Center.

Who makes Ethyl Chloride Topical Aerosol Anesthetic?

Ethyl Chloride Topical Aerosol Anesthetic is developed by Brooke Army Medical Center (see full Brooke Army Medical Center pipeline at /company/brooke-army-medical-center).

Is Ethyl Chloride Topical Aerosol Anesthetic also known as anything else?

Ethyl Chloride Topical Aerosol Anesthetic is also known as Study Device or Product B.

What development phase is Ethyl Chloride Topical Aerosol Anesthetic in?

Ethyl Chloride Topical Aerosol Anesthetic is in Phase 1.

Related